1. Lower respiratory tract: ↑ abundance after checkpoint inhibitors/radiotherapy; 2. Inflammation: Activates local lung immunity, promotes neutrophils/IL-17/TNF-α, exacerbates pneumonia/fibrosis. Here, IL17A is linked to pneumonia.